Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against EyePoint, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of EyePoint, Inc. (“EyePoint” or “the Company”) (NASDAQ: EYPT). Investors who purchased EyePoint securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether EyePoint has violated federal securities laws.
EyePoint Investigation Details
On May 6, 2026, EyePoint, Inc.’s President and CEO Jay Duker stated, “We are confident that our clinically-rigorous, derisked and patient-centric approach will continue to reinforce DURAVYU’s best-in-class potential.” Then, on June 9, 2026, Duker stated that the Company “remain[s] quite confident and quite optimistic in the results, and we think we can make a difference for patients,” while describing DURAVYU as a “derisked asset.” Then, in August 2026, EyePoint disclosed that DURAVYU failed to meet the prespecified primary endpoint—change in best-corrected visual acuity versus on-label aflibercept—in the full dataset of its Phase 3 LUGANO trial for wet age-related macular degeneration. The Company also disclosed an ad hoc analysis excluding a 4% asymmetric patient cohort. Following this news, EyePoint’s stock price opened approximately 70% lower.
What’s Next for EyePoint Investors?
If you are aware of any facts relating to this investigation or purchased EyePoint securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
EYPT — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”